Abstract: It is an object of the present invention to provide a bacterial strain that can decrease the amount of an intermediate Compound P converted into Metabolite M and efficiently accumulate Compound P in a medium that is not supplemented with Metabolite M or the final product generated from Metabolite M. The present invention provides a prokaryotic organism having all features (a) to (d) as defined in the specification so as to accumulate Compound P by regulating expression level of Enzyme X that converts Compound P as an intermediate metabolite into Metabolite M in a biosynthetic pathway in which Metabolite M indispensable for the growth is produced from a carbon source.

Abstract: It is an object of the present invention to provide a bacterial strain that can decrease the amount of an intermediate Compound P converted into Metabolite M and efficiently accumulate Compound P in a medium that is not supplemented with Metabolite M or the final product generated from Metabolite M. The present invention provides a prokaryotic organism having all features (a) to (d) as defined in the specification so as to accumulate Compound P by regulating expression level of Enzyme X that converts Compound P as an intermediate metabolite into Metabolite M in a biosynthetic pathway in which Metabolite M indispensable for the growth is produced from a carbon source.

Abstract: It is an object of the present invention to provide a bacterial strain that can decrease the amount of an intermediate Compound P converted into Metabolite M and efficiently accumulate Compound P in a medium that is not supplemented with Metabolite M or the final product generated from Metabolite M. The present invention provides a prokaryotic organism having all features (a) to (d) as defined in the specification so as to accumulate Compound P by regulating expression level of Enzyme X that converts Compound P as an intermediate metabolite into Metabolite M in a biosynthetic pathway in which Metabolite M indispensable for the growth is produced from a carbon source.

Abstract: TPA-DHD can be produced by using, as a raw material, terephthalic acid salt that contains 0.5 times or more and twice or less the amount of potassium based on all of the terephthalic acids contained in the terephthalic acid salt in terms of moles and by using a microorganism expressing terephthalate 1,2-dioxygenase. Further, TPA-DHD can be converted into protocatechuic acid by TPA-DHD dehydrogenase and protocatechuic acid can be converted into gallic acid by para-hydroxybenzoate hydroxylase. In addition, by subjecting waste polyesters to heat treatment in an ethylene glycol solvent or 1-butanol solvent containing potassium hydroxide, such polyesters can be efficiently depolymerized, and potassium terephthalate suitable to chemical production by the microorganism can be prepared.

Abstract: It is an object of the present invention to provide a bacterial strain that can decrease the amount of an intermediate Compound P converted into Metabolite M and efficiently accumulate Compound P in a medium that is not supplemented with Metabolite M or the final product generated from Metabolite M. The present invention provides a prokaryotic organism having all features (a) to (d) as defined in the specification so as to accumulate Compound P by regulating expression level of Enzyme X that converts Compound P as an intermediate metabolite into Metabolite M in a biosynthetic pathway in which Metabolite M indispensable for the growth is produced from a carbon source.

Abstract: TPA-DHD can be produced by using, as a raw material, terephthalic acid salt that contains 0.5 times or more and twice or less the amount of potassium based on all of the terephthalic acids contained in the terephthalic acid salt in terms of moles and by using a microorganism expressing terephthalate 1,2-dioxygenase. Further, TPA-DHD can be converted into protocatechuic acid by TPA-DHD dehydrogenase and protocatechuic acid can be converted into gallic acid by para-hydroxybenzoate hydroxylase. In addition, by subjecting waste polyesters to heat treatment in an ethylene glycol solvent or 1-butanol solvent containing potassium hydroxide, such polyesters can be efficiently depolymeried, and potassium terephthalate suitable to chemical production by the microorganism can be prepared.

Abstract: In accordance with the present invention, there are provided (1) various cell lines derived from hypothalamus and Langerhans islets of mammals, (2) process for producing an active peptide and expression cloning system of active peptide precursor gene using the cell line as a host, (3) a method of screening or evaluating a substance capable of acting on the cells using the cell line, (4) a method of screening or isolating a useful gene or useful peptide using the cell line and (5) a highly-sensitive and simple assay system for GPCR ligand used in the above expression cloning system.

Abstract: The invention provides a novel species of ?-1,3-fucosyltransferase expressed by a gene cloned from animal cells, a cDNA coding for the ?-1,3-fucosyltransferase, a method of detecting, or inhibiting the production of, the ?-1,3-fucosyltransferase which involves the use of the cDNA, a recombinant vector containing the DNA as an insert, a cell harboring the recombinant vector, and a method of producing same. The ?-1,3-fucosyltransferase of the invention is useful in the production of carbohydrate chains having useful physiological activity, for example sialyl Lewis x, and modifications thereof.

Abstract: The present invention provides pharmaceutical preparations for anti-inflammation, anti-infection, inhibition of cancer metastasis etc., foods such as dairy products etc., and a method for improving proteins, as well as a method for diagnosis of inflammatory diseases and cancer malignancy. According to the present invention, there can be provided a polypeptide having poly-N-acetyllactosamine sugar chains synthesis-related activity, a process for producing the polypeptide, DNA coding for the polypeptide, a process for producing the DNA, a recombinant vector having the DNA integrated therein, a transformant carrying the recombinant vector, an antibody recognizing the polypeptide, a process for producing poly-N-acetyllactosamine sugar chains by use of the DNA or the polypeptide, diagnosis and treatment of diseases such as inflammations, cancers etc.

Abstract: In accordance with the present invention, there are provided (1) various cell lines derived from hypothalamus and Langerhans islets of mammals, (2) process for producing an active peptide and expression cloning system of active peptide precursor gene using the cell line as a host, (3) a method of screening or evaluating a substance capable of acting on the cells using the cell line, (4) a method of screening or isolating a useful gene or useful peptide using the cell line and (5) a highly-sensitive and simple assay system for GPCR ligand used in the above expression cloning system.

Abstract: In accordance with the present invention, there are provided (1) various cell lines derived from hypothalamus and Langerhans islets of mammals, (2) process for producing an active peptide and expression cloning system of active peptide precursor gene using the cell line as a host, (3) a method of screening or evaluating a substance capable of acting on the cells using the cell line, (4) a method of screening or isolating a useful gene or useful peptide using the cell line and (5) a highly-sensitive and simple assay system for GPCR ligand used in the above expression cloning system.

Abstract: The invention provides a novel ?-2,8-sialyltransferase expressed by a gene cloned from animal cells, a cDNA coding for the ?-2,8-sialyltransferase, a method of detecting, or suppressing the production of ?-2,8-sialyltransferase by using the cDNA, a recombinant vector containing the DNA as an insert and cells harboring the recombinant vector as well as methods of preparing same. The ?-2,8-sialyltransferase of the invention is useful, for example, in the production of carbohydrate chains having a useful physiological activity, for example the ganglioside GD3, and modifications thereof.

Abstract: The invention provides a novel species of ?-1,3-fucosyltransferase expressed by a gene cloned from animal cells, a cDNA coding for the ?-1,3-fucosyltransferase, a method of detecting, or inhibiting the production of, the ?-1,3-fucosyltransferase which involves the use of the cDNA, a recombinant vector containing the DNA as an insert, a cell harboring the recombinant vector, and a method of producing same. The ?-1,3-fucosyltransferase of the invention is useful in the production of carbohydrate chains having useful physiological activity, for example sialyl Lewis x, and modifications thereof.

Abstract: The invention provides a novel species of ?-1,3-fucosyltransferase expressed by a gene cloned from animal cells, a cDNA coding for the ?-1,3-fucosyltransferase, a method of detecting, or inhibiting the production of, the ?-1,3-fucosyltransferase which involves the use of the cDNA, a recombinant vector containing the DNA as an insert, a cell harboring the recombinant vector, and a method of producing same. The ?-1,3-fucosyltransferase of the invention is useful in the production of carbohydrate chains having useful physiological activity, for example sialyl Lewis x, and modifications thereof.

Abstract: A novel DNA whose expression level fluctuates in leukocytes of IgA nephropathy patients in comparison with leukocytes of healthy persons, a process for isolating the DNA, a novel protein encoded by the DNA, an antibody recognizing the protein, methods for detecting the protein and the DNA, and methods of diagnosis and treatment of IgA nephropathy.

Abstract: A method of determining a genetic structure which includes a process of, after having predicted coding regions which create a transcription unit, proceeding to determine a translation start codon; a method of determining a genetic structure which includes a process of selecting a plurality of pairs of codons of which the difference between the appearance frequencies and those of the codons which have the reverse complementary sequence within the nucleotide sequences of a plurality of coding regions which have already been determined is great, and of deciding that those coding regions which have a large number of codons for which the frequency at which each pair appears is high are true coding regions; a method of determining a genetic structure where the GC content of a nucleotide sequence exceeds 50%, including a process of deciding as false one for which the first and the third GC content of the codons within a coding region are less than a predetermined value; a program for performing these; a recording me

Abstract: The present invention relates to a novel DNA related to IgA nephropathy obtained by a differential display method [FEBS Letters, 351, 231 (1994)] taking note of an mRNA whose expression level fluctuates in leukocytes of IgA nephropathy patients in comparison with leukocytes of healthy persons, a process for isolating the DNA, a method for detecting the DNA, a novel protein encoded by the DNA, an antibody recognizing the protein, a method for detecting the protein, and diagnosis and treatment of IgA nephropathy.

Abstract: The present invention relates to a novel protein isolated from the leukocyte of IgA nephropathy patients, and DNA encoding the protein. It also relates to an oligonucleotide based on the nucleotide sequence complementary with the DNA, an antibody which specifically reacts with the protein and, furthermore, diagnostic and therapeutic drugs of IgA nephropathy comprising it.

Abstract: The invention provides a novel &agr;-2,8-sialyltransferase expressed by a gene cloned from animal cells, a cDNA coding for the &agr;-2,8-sialyltransferase, a method of detecting, or suppressing the production of &agr;-2,8-sialyltransferase by using the cDNA, a recombinant vector containing the DNA as an insert and cells harboring the recombinant vector as well as methods of preparing same. The &agr;-2,8-sialyltransferase of the invention is useful, for example, in the production of carbohydrate chains having a useful physiological activity, for example the ganglioside GD3, and modifications thereof.

Abstract: A novel DNA whose expression level fluctuates in leukocytes of IgA nephropathy patients in comparison with leukocytes of healthy persons, a process for isolating the DNA, a novel protein encoded by the DNA, an antibody recognizing the protein, methods for detecting the protein and the DNA, and methods of diagnosis and treatment of IgA nephropathy.